Nephrada · IGAN · United Kingdom · HTA assessor · captured by Dr. Anna Becker on 14 Aug 2026 · reviewed by Dr. Marcus Lindqvist on 15 Aug 2026
Verbatim as captured; never edited
NICE technical team indicated during a scientific advice meeting that proteinuria reduction alone would be treated as high uncertainty and that they would expect eGFR slope data at 2 years for a positive recommendation.
Human-approved by Dr. Marcus Lindqvist on 15 Aug 2026
NICE signals proteinuria alone insufficient; 2-year eGFR slope expected for positive recommendation. Increases urgency of GLOMERULAR-REG.
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 5 | 15% | 15.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | Critical 82 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 15 Aug 2026, 11:22 UTC | Route | MLDr. Marcus Lindqvist | routedTo | — → Market Access | NICE scientific advice; HTA relevance | UI |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
14 Aug 2026 · Dr. William Jensen, NICE technical team · MSL Dr. Anna Becker
Insight
Reviewed 15 Aug 2026 by Dr. Marcus Lindqvist
Market Access · Sara Holm · due 30 Sept 2026 · At risk
RWE project · Dr. Nikolai Petrov · Blocked
Undated · Under review
Outcome
Decision · DEC-0006
Closure